Welcome to our dedicated page for Lyra Therapeutics news (Ticker: LYRA), a resource for investors and traders seeking the latest updates and insights on Lyra Therapeutics stock.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) is a clinical-stage therapeutics company focused on advancing and commercializing innovative drug and delivery solutions specifically designed for ear, nose, and throat diseases. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics leverages its proprietary XTreo™ technology platform to deliver sustained medication directly to the targeted tissue via a single administration.
The company's primary product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices targeting the treatment of chronic rhinosinusitis (CRS). These candidates are formulated to provide up to six months of continuous drug therapy through a non-invasive, in-office procedure. LYR-210 is intended for patients who have not undergone sinus surgery, while LYR-220 is designed for those who have had prior ethmoid sinus surgery.
Recent advancements include the BEACON Phase 2 clinical trial of LYR-220, which demonstrated significant improvement in CRS patients post-surgery, and the ongoing ENLIGHTEN Phase 3 clinical trials of LYR-210, targeting patients who have not had surgery. Lyra's financial condition remains robust, with cash and short-term investments totaling $102.6 million as of September 30, 2023, expected to support operations into the first quarter of 2025.
Lyra Therapeutics continues to innovate within the CRS treatment landscape, aiming to address the unmet medical needs of the estimated four million CRS patients in the United States who fail to respond to existing treatments annually. The company remains committed to advancing its product portfolio and achieving regulatory milestones to bring these therapies to market.
Lyra Therapeutics (NASDAQ: LYRA) reported third-quarter 2022 financial results, showing a net loss of $14.8 million, up from $11.1 million a year prior. Cash reserves stand at $109.6 million, projected to fund operations through mid-2024. The company prioritizes the ENLIGHTEN I Phase 3 trial for LYR-210 in chronic rhinosinusitis, with enrollment expected to complete by mid-2023. Enrollment in the ENLIGHTEN II trial will temporarily pause to align with in-house manufacturing timelines, expected to resume in Q3 2023. Positive initial data from the BEACON Phase 2 trial of LYR-220 were also highlighted.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) has announced an equity-based award for its new Senior Vice President of Investor Relations and Communications, Ellen Cavaleri, in accordance with Nasdaq Listing Rule 5635(c)(4). This inducement grant includes a non-qualified stock option to purchase 110,000 shares of the Company's common stock, approved by its independent directors. The company aims to leverage its XTreo™ platform for precise delivery of medications targeting ear, nose, and throat conditions, with ongoing product candidates like LYR-210 and LYR-220.
Lyra Therapeutics announced significant progress in its Phase 2 BEACON clinical trial for LYR-220, targeting chronic rhinosinusitis (CRS) patients who've undergone previous surgeries. The trial's Part 1 showed a 37% mean improvement in SNOT-22 scores among six patients over six weeks. With the first patient now dosed in the randomized Part 2 stage, the trial aims to evaluate safety and efficacy against a control group. Lyra is positioning LYR-220 as a non-invasive treatment alternative for the estimated 4 million CRS patients needing continuous therapy.
Lyra Therapeutics (LYRA) presented promising data from its Phase 2 LANTERN study at the American Rhinologic Society meeting, indicating that LYR-210 significantly reduced symptoms of chronic rhinosinusitis (CRS) in patients treated with 7500μg dosage. Improved outcomes were noted in key symptom areas: nasal blockage, discharge, and facial pressure. The study showed a strong correlation between 3 cardinal symptoms and SNOT-22 scores, emphasizing LYR-210's potential to enhance quality of life. The company continues to advance LYR-210 in the Phase 3 ENLIGHTEN program, aiming to provide a non-invasive treatment option for CRS.
Lyra Therapeutics (NASDAQ: LYRA) has announced the enrollment of the first patient in the Phase 3 ENLIGHTEN II clinical trial for LYR-210, targeting chronic rhinosinusitis (CRS) patients. This study aims to assess the efficacy and safety of LYR-210 as a non-invasive alternative to sinus surgery. The trial will involve 180 participants, comparing LYR-210 against a control, with the primary endpoint being symptom improvement over 24 weeks. With 14 million CRS patients in the U.S., LYR-210 seeks to address the significant unmet need among those not responding to current treatments.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 12:00 p.m. EDT in New York. CEO Maria Palasis will present in person. The conference takes place from September 12-14, 2022, at the Lotte New York Palace Hotel, where one-on-one investor meetings will also be held. Lyra's XTreo™ platform enables localized drug delivery for ENT conditions, with LYR-210 and LYR-220 targeting chronic rhinosinusitis in late clinical stages.
Lyra Therapeutics (Nasdaq: LYRA) announced it will present additional Phase 2 results from the LANTERN study for LYR-210, its lead candidate for chronic rhinosinusitis, at the American Rhinologic Society Annual Meeting on September 9-10, 2022. The presentations will include findings on long-acting corticosteroid matrices and correlations in symptom scoring. Chronic Rhinosinusitis impacts over 14 million Americans, adding significant healthcare costs, estimated at $60 billion globally. The company aims to address treatment gaps for patients who do not respond to current therapies.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) reported financial results for Q2 2022, highlighting significant progress in its clinical programs for chronic rhinosinusitis (CRS). The pivotal ENLIGHTEN Phase 3 trial for LYR-210 is enrolling patients, while the BEACON Phase 2 trial for LYR-220 continues recruitment. Lyra secured $96.3 million in April 2022, extending its cash runway until mid-2024. Cash and equivalents reached $120.7 million by June 30, 2022. The net loss for the quarter was $14.5 million, up from $11.0 million in Q2 2021, influenced by increased R&D and administrative expenses.
Lyra Therapeutics (Nasdaq: LYRA) announced its participation at the William Blair Biotech Focus Conference 2022, taking place from July 12-13 at The St. Regis New York. CEO Maria Palasis, Ph.D., will engage in a fireside chat during the event, which also includes one-on-one meetings with investors. The webcast of the discussion can be accessed on the company's Investor Relations website for 30 days post-event. Lyra employs its XTreo™ platform for localized medication delivery, currently developing therapeutics for chronic rhinosinusitis, including LYR-210 and LYR-220.
Lyra Therapeutics, Inc. (Nasdaq: LYRA) appoints Dr. Richard Nieman as Chief Medical Officer effective July 11, 2022. Dr. Nieman brings over 25 years of drug development experience, previously holding senior roles in major pharmaceutical companies. His expertise will be crucial as Lyra's lead candidate, LYR-210, advances in Phase 3 trials for chronic rhinosinusitis. This leadership change aims to enhance the company’s capabilities in bringing new treatments to market. Additionally, Dr. Nieman will receive a stock option grant as part of his compensation package, totaling 230,000 shares.
FAQ
What is the current stock price of Lyra Therapeutics (LYRA)?
What is the market cap of Lyra Therapeutics (LYRA)?
What does Lyra Therapeutics, Inc. specialize in?
What are the primary product candidates of Lyra Therapeutics?
What is the XTreo™ technology platform?
What is the latest update on the BEACON Phase 2 clinical trial?
What are the ENLIGHTEN Phase 3 clinical trials?
Where is Lyra Therapeutics headquartered?
When was Lyra Therapeutics founded?
How long does the drug therapy from LYR-210 and LYR-220 last?
How does Lyra Therapeutics fund its operations?
What is chronic rhinosinusitis (CRS)?
